O
INSY

OrbiMed’s Insys Therapeutics, Inc. INSY Stock Holding History

OrbiMed’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,028,354
Closed -$30.5M – 162
2018
Q3 		$30.5M Sell
3,028,354
-483,190
-14% -$3.85M 0.37% 70
2018
Q2 		$25.4M Hold
3,511,544
– – 0.3% 73
2018
Q1 		$21.2M Sell
3,511,544
-1,895,300
-35% -$15.6M 0.26% 79
2017
Q4 		$52M Sell
5,406,844
-764,596
-12% -$5M 0.66% 47
2017
Q3 		$54.8M Hold
6,171,440
– – 0.52% 59
2017
Q2 		$78.1M Buy
6,171,440
+100,000
+2% +$1.18M 0.82% 40
2017
Q1 		$63.8M Hold
6,071,440
– – 0.72% 44
2016
Q4 		$55.9M Buy
6,071,440
+569,200
+10% +$6.43M 0.71% 42
2016
Q3 		$64.9M Buy
5,502,240
+814,000
+17% +$12.4M 0.74% 50
2016
Q2 		$60.7M Buy
4,688,240
+130,500
+3% +$1.9M 0.63% 47
2016
Q1 		$72.9M Buy
4,557,740
+191,000
+4% +$3.63M 0.77% 40
2015
Q4 		$125M Buy
4,366,740
+284,940
+7% +$7.89M 1.13% 31
2015
Q3 		$116M Buy
4,081,800
+1,458,800
+56% +$53.7M 1.17% 30
2015
Q2 		$94.2M Buy
2,623,000
+136,600
+5% +$4.25M 0.79% 38
2015
Q1 		$72.3M Hold
2,486,400
– – 0.62% 46
2014
Q4 		$52.4M Buy
2,486,400
+1,015,200
+69% +$20.1M 0.5% 47
2014
Q3 		$28.5M Buy
+1,471,200
New +$23.1M 0.3% 61

Other funds holding INSY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

OrbiMed's INSY Position: Q4 2018 in Review

OrbiMed sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 3,028,354 shares — an estimated $30.5M sold.

OrbiMed first reported a position in INSY in Q3 2014 and held it in 17 quarters. The position peaked at $125M in Q4 2015. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • OrbiMed reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • OrbiMed sold 3,028,354 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $30.5M.
  • OrbiMed first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 17 quarters.
  • OrbiMed's Insys Therapeutics, Inc. position peaked at $125M in Q4 2015.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.